Navigation Links
Experimental Drug Eases Symptoms of Mild Alzheimer's
Date:4/30/2008

Tarenflurbil lessened decline in functional ability, British study concludes

WEDNESDAY, April 30 (HealthDay News) -- Patients with mild Alzheimer's disease who took 800 milligrams of the drug tarenflurbil twice a day had less decline in functional ability than those who took a placebo, according to a British phase II trial.

The findings support phase III studies of the drug at this dose, the researchers said. Tarenflurbil reduces production of 42-amino-acid peptide, which is believed to initiate brain damage characteristic of Alzheimer's disease. Previous research had found the drug prevented learning and memory defects in mice with Alzheimer's disease.

In this study, 210 patients were randomly assigned to receive either 400 milligrams of tarenflurbil twice per day (69 patients), 800 milligrams of tarenflurbil twice per day (70 patients), or a placebo (71 patients).

Patients with mild Alzheimer's who took 800 milligrams of tarenflurbil for 24 months had lower rates of decline than those who were in the placebo group for the first 12 months of the study and either tarenflurbil group for the last 12 months of the study.

Common side effects included diarrhea, nausea and dizziness.

The researchers concluded that "800 mg tarenflurbil twice per day was well-tolerated for up to 24 months of treatment, with evidence of a dose-related effect on measures of daily activities and global function in patients with mild AD ... these findings justify phase III studies of tarenfurbil at the 800 mg twice daily dose in patients with mild AD."

The study was published online in The Lancet Neurology.

The findings are sufficient to support Phase III studies of the drug, Dr. Paul Aisen of the University of California, San Diego, wrote in an accompanying commentary.

"With the need so enormous, and the potential effect of the benefit suggested [although not proven] by these phase II results, the effort is indeed justified despite the substantial uncertainty. In a few months, we will learn whether tarenflurbil will be the first anti-amyloid intervention to be efficacious in a pivotal trial," Aisen wrote.

More information

The U.S. National Institute on Aging has more about Alzheimer's disease.



-- Robert Preidt



SOURCE: The Lancet, news release, April 29, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Experimental Blood Substitutes Unsafe, Study Finds
2. Honda to Showcase Experimental Walking Assist Device
3. Experimental Alzheimers Drug Shows Promise
4. Experimental drug shows promise in treating certain lymphomas
5. Experimental Cancer Vaccines Show Promise
6. Gourmetceuticals Presents Findings on Science You Can Eat at Experimental Biology 2008
7. Cavities in Children Reduced Over 60 Percent by New Experimental Chewable Mints
8. Gourmetceuticals to Present Data from Four Studies at Experimental Biology 2008
9. 52 minority scientists receive travel fellowships to Experimental Biology 2008
10. Experimental Biology 2008 Todays Research: Tomorrows Health, April 5-9
11. Experimental Vaccine Halts Prostate Cancer in Mice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... 2016 , ... Austin residents seeking Mohs surgery services, can now turn to ... Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to ... fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort to ... treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain management ... (SCD) is a disorder of the red blood cells, which can cause episodes of ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Comfort Keepers® of ... Cancer Society and the Road To Recovery® program to drive cancer patients to and ... other adults to ensure the highest quality of life and ongoing independence. Getting ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative ... has initiated cultivation and processing operations at its production facility, and opened its ... Puradigm is the manufacturer of a complete system of proactive air and surface ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... 2016 Jazz Pharmaceuticals plc (Nasdaq: ... Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), ... Inc. ("Celator"; Nasdaq: CPXX ) expired effective ... As previously announced on May 31, 2016, ... agreement under which Jazz Pharmaceuticals has commenced a tender ...
(Date:6/26/2016)... 2016 Story Highlights: ... within the health care industry is causing providers to ... , Deloitte offers a suite of solutions for health ... efficient cost optimization: labor resource analysis, revenue cycle optimization ... better outcomes and better economics ...
(Date:6/24/2016)... , June 24, 2016  Collagen Matrix, Inc., ... development and manufacturing of collagen and mineral based ... today that Bill Messer has joined ... to further leverage the growing portfolio of oral ... Bill joins the Collagen Matrix executive ...
Breaking Medicine Technology: